Profiling tumor counterattack: do Fas ligand-containing microvesicles reduce anticancer immunity?
Bohana-Kashtan
Osnat
O
Division of Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center, Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Civin
Curt I
CI
D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000276:immunology* / Q000473:pathology; D022162:Cytoplasmic Vesicles / Q000378:metabolism*; D053222:Fas Ligand Protein; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D009062:Mouth Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins